Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study.
De Castro N, Brun A, Sellier P, Hamet G, Mechaï F, Garrait V, Chabrol A, Bouldouyre MA, Froguel E, Troisvallets D, Caraux-Paz P, Delaugerre C, Rozenbaum W, Molina JM. De Castro N, et al. Among authors: troisvallets d. AIDS Res Ther. 2023 Jan 3;20(1):1. doi: 10.1186/s12981-022-00499-4. AIDS Res Ther. 2023. PMID: 36597160 Free PMC article.
HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome.
Boccara F, Mary-Krause M, Potard V, Teiger E, Lang S, Hammoudi N, Chauvet M, Ederhy S, Dufour-Soulat L, Ancedy Y, Nhan P, Adavane S, Steg PG, Funck-Brentano C, Costagliola D, Cohen A; PACS‐HIV (Prognosis of Acute Coronary Syndrome in HIV‐Infected Patients) Investigators †. Boccara F, et al. J Am Heart Assoc. 2020 Sep;9(17):e017578. doi: 10.1161/JAHA.119.017578. Epub 2020 Aug 26. J Am Heart Assoc. 2020. PMID: 32844734 Free PMC article.
Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C; CNA3007 Study Group. Matheron S, et al. Among authors: troisvallets d. Antivir Ther. 2003 Apr;8(2):163-71. Antivir Ther. 2003. PMID: 12741629 Clinical Trial.
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM; VIKING-3 Study Group. Castagna A, et al. J Infect Dis. 2014 Aug 1;210(3):354-62. doi: 10.1093/infdis/jiu051. Epub 2014 Jan 19. J Infect Dis. 2014. PMID: 24446523 Free PMC article. Clinical Trial.
Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study.
Force G, Ghout I, Ropers J, Carcelain G, Marigot-Outtandy D, Hahn V, Darchy N, Defferriere H, Bouaziz-Amar E, Carlier R, Dorgham K, Callebert J, Peytavin G, Delaugerre C, de Truchis P; NEURO+3 STUDY GROUP. Force G, et al. J Antimicrob Chemother. 2021 Feb 11;76(3):743-752. doi: 10.1093/jac/dkaa473. J Antimicrob Chemother. 2021. PMID: 33179033
A generalized additive model to disentangle age and diagnosis-specific cohort effects in psychological and behavioral outcomes in people living with HIV: the French cross-sectional ANRS-VESPA2 survey.
Sagaon-Teyssier L, Vilotitch A, Mora M, Maradan G, Guagliardo V, Suzan-Monti M, Dray-Spira R, Spire B; VESPA2 study group. Sagaon-Teyssier L, et al. BMC Public Health. 2019 May 17;19(1):590. doi: 10.1186/s12889-019-6905-z. BMC Public Health. 2019. PMID: 31101129 Free PMC article.
22 results